ファージディスプレイ法による自己免疫疾患の自己抗原の探索 by Niwa Mikio & 丹羽 幹夫
Isolation of Novel Autoantigens by Lambda
Phage Surface Display
著者 Niwa Mikio
year 2018
その他のタイトル ファージディスプレイ法による自己免疫疾患の自己
抗原の探索
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2017
報告番号 12102甲第8573号
URL http://doi.org/10.15068/00152277
  
 
 
 
 
Isolation of Novel Autoantigens by Lambda Phage Surface Display 
 
 
 
 
 
 
 
 
 
January 2018 
 
 
 
 
 
Mikio NIWA 
  
  
 
 
 
Isolation of Novel Autoantigens by Lambda Phage Surface Display 
 
 
 
 
 
 
A Dissertation Submitted to 
the Graduate School of Life and Environmental Sciences, 
the University of Tsukuba 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy in Biological Science 
(Doctoral Program in Biological Sciences) 
 
 
 
 
Mikio NIWA 
 
i 
 
Table of Contents 
 
Abstract ....................................................................................................................................1 
Abbreviations ...........................................................................................................................4 
General Introduction ................................................................................................................6 
Chapter 1: Affinity selection of cDNA libraries by  phage surface display 
 Summary ....................................................................................................................13 
Introduction ................................................................................................................14 
Materials and Methods ...............................................................................................16 
Results ........................................................................................................................21 
Discussion ..................................................................................................................26 
Conclusion .................................................................................................................29 
Figures, Tables ...........................................................................................................30 
Chapter 2: Novel Autoantigens Recognized by Sera and Synovial Fluids from Patients with 
Rheumatoid Arthritis: Isolation by Using Bacteriophage  Surface Display 
 Summary ....................................................................................................................35 
Introduction ................................................................................................................36 
Materials and Methods ...............................................................................................38 
Results ........................................................................................................................40 
Discussion ..................................................................................................................42 
Conclusion .................................................................................................................44 
Figure, Tables .............................................................................................................45 
General Discussion ................................................................................................................48 
Acknowledgements ................................................................................................................54 
References ..............................................................................................................................55 
1 
 
Abstract 
 
The appearance of antibodies against components of the individual's own body, called 
autoantibodies, is the most important feature of autoimmune diseases. However, 
autoantibodies are raised against various molecules, and it is revealed that in systemic 
autoimmune diseases many autoantibodies recognize intracellular molecules, such as 
cytoplasmic proteins and nuclear proteins, and these antigens are called intracellular 
autoantigens. 
  To date, intracellular autoantigens have been discovered by conventional methods 
such as immunoprecipitation and expression screening of cDNA libraries. However, both 
methods require tedious processes, making it difficult to carry out a number of independent 
screenings, and the probability of success is low. Phage display using filamentous M13 phage 
was proposed by G. P. Smith in 1985. In this new method, a foreign DNA product is 
displayed on the surface of the phage particle. The desired phage-expressed autoantigens can 
be enriched specifically from large cDNA libraries by repeat binding to target autoantibodies 
and phage amplification. However, although this technique is expected to work well in the 
search for autoantigens, the discovery of intracellular autoantigens using this method has not 
been reported. One of the reasons for this unexpected result is that proteins with low 
membrane permeability tend not to be displayed on the surface of the phage. 
  To overcome this problem, Maruyama developed a novel bacteriophage lambda 
surface display vector, foo (fusion on outside). It is expected that both secreting and 
intracellular proteins can be expressed while maintaining their native conformation and 
function, because foreign proteins need not pass through a membrane when foo phage 
assembly occurs in cytoplasm. 
  In this study, I would like to demonstrate that intracellular autoantigens can be 
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selected from cDNA library made by foo vector using sera of autoimmune diseases. 
Moreover, the first challenge so far will be to discover novel autoantigens.  
  The strategy for searching for autoantigens is as follows: 1) mRNA is purified from a 
cultured human cell line or lesional tissue from disease patients, then cDNA is synthesized 
and incorporated into foo vector and a cDNA library is constructed by the in vitro 
packaging method for forming phage particles. 2) a phage expressed autoantigen is enriched 
from the cDNA library by autoantibodies in the patient’s serum. 3) cDNA inserts in selected 
phages are determined and searched within the DNA data-base. 4) The reactivity of the 
selected phages to serum from patients of target disease is compared to that of other relative 
diseases and of healthy donors. Finally, I evaluate whether the protein expressed by the 
selected phage is disease-specific or not. 
  In the first chapter, as a model experiment, I carried out a search for phages encoding 
intracellular autoantigens recognized in sera from patients with Sjögren's syndrome (SjS) 
from cultured cell cDNA libraries made with foo. As a result, I successfully isolated cDNA 
clones that encode some intracellular autoantigens recognized by SjS sera. Among these, four 
clones expressed autoantigens previously identified in SjS, namely SS-B/La, hRPA-70, 
NOR-90, and Ki-67 antigen, and three clones, SMN, pM5, and TFG, encoded proteins 
previously not known as autoantigens in any autoimmune disease. In particular, I speculate 
that the anti-SMN antibody may be a novel anti-nuclear antibody. These results were the first 
demonstration that novel autoantigens can be found in a cDNA library using the phage 
display technique. 
  Moreover, in the second chapter, I isolated novel autoantigens by using synovial 
fluids and sera from patients with rheumatoid arthritis (RA). As a result, three proteins, sorcin, 
IGFBP-4, and SHLP-1, were found as novel autoantigens that are specific for RA. 
Interestingly, it should be noted that autoantibody against IGFBP-4 may participate in the 
3 
 
progression of RA. 
  In this study, I prove that cytoplasmic proteins can be efficiently selected as 
autoantigens of autoimmune diseases from the cDNA phage display library using the λfoo 
vector. Besides, I could determine some novel autoantigen/autoantibody sets. Thus, this 
technology is expected to elucidate the etiology and mechanisms producing autoantibodies in 
autoimmune diseases. 
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Abbreviations 

ALS   acid-labile subunit 
ANAs   anti-nuclear autoantibody
Gal   -galactosidase 
BCOADC-E2  branched chain 2-oxo-acid dehydrogenase complex-E2 
ELISA   enzyme-linked immunosorbent assay 
ER   endoplasmic reticulum 
IGF   Insulin-like growth factor 
IGFBP   insulin-like growth factor binding protein 
IgG    immunoglobulin-G 
MCTD   mixed connective tissue disease 
NAA   natural autoantibody 
NOR-90  nucleolus organizer region autoantigen 
NuMA1  type-1 nuclear mitotic apparatus protein 
OA   osteoarthritis 
PBC   primary biliary cirrhosis 
pfu   bacteriophage plaque-forming unit 
RA   rheumatoid arthritis 
RF   rheumatoid factor 
RPA   human replication protein A 
SF   synovial fluid 
SHLP   small humanin like peptide 
SjS   Sjögren's syndrome 
SLE   systemic lupus erythematosus 
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SMN   survival motor neuron gene product 
snRNP    small nuclear ribonucleoprotein complex 
SSc   systemic sclerosis 
TFG   TRK-fused gene product 
UPR   unfolded protein response 
XGal   5-bromo-4-chloro-3-indolyl -D-galactopyranoside 
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General Introduction 
 
What is autoimmune disease? 
By default, the immune system remains inactive based on the principle of “immune 
tolerance,” meaning it does not respond to a self-antigen. An autoimmune disease causes 
aberrant behavior and dysfunction in various tissues in one’s own body by a breakdown in 
tolerance. There are still many questions regarding the mechanism behind immunological 
tolerance failure, but several hypotheses have been proposed, including apoptotic abnormality, 
abnormality of regulatory T-cells, and the molecular mimicry mechanism (Lleo et al., 2010). 
An antibody turning on one’s own body tissues is called an autoantibody. The 
existence of autoantibodies has also been reported in the serum of healthy persons, and this is 
called natural autoantibody (NAA). The functions of NAA are not clear, but NAA may 
participate in various activities, such as regulation of immune response, and removing aged 
or damaged tissue in healthy persons (Silosi et al., 2016). However, natural autoantibodies 
are particularly of the IgM isotype, have low affinity, and are poly-specific while 
autoantibodies in autoimmune disease tend to be isotype IgG, show high affinity and 
specificity, and have a characteristic function, such as removing alien substances, viruses and 
bacteria. However, even though autoantibodies are an important phenomenon in all 
autoimmune diseases, the mechanism by which autoantibodies affect the clinical condition is 
still unclear, as is the reason why a particular autoantibody is produced in a specific disease. 
 
Autoantibodies to intracellular antigens 
Autoimmune disease have long been classified as organ-specific or systemic, 
depending on whether or not the autoimmune response is directed against one organ or 
apparatus, as in autoimmune Hashimoto’s thyroiditis (Burek, 2010). 
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Autoantibodies are targeted against various molecules, such as nucleic acids, 
polysaccharides and proteins, and these antigens are ubiquitously located, in nucleus or 
cytoplasm, on membranes or in the extracellular space. However, it is conspicuous that many 
autoantibodies in systemic autoimmune diseases recognize intracellular molecules, in 
particular nuclear molecules. The latter are called anti-nuclear antibodies (ANAs).  
These intracellular antigens raise the question how the immune response is mounted, why 
they are specifically targeted in certain disease subsets and inherently, how they are exposed 
to B- or T-cells so these can mature and produce autoantibodies. To understand these 
questions, several hypotheses have been explored. Among these hypotheses, three 
representative models are displayed in Fig. 1: (A) exposure by abnormal clearance of 
apoptosis/necrosis; (B) epitope modification; (C) molecular mimicry (Suurmond et al., 2015). 
However, intracellular autoantigens are expressed ubiquitously in various cell types, and 
specific subsets are preferentially targeted in different systemic autoimmune diseases. For 
example, SS-B/La in Sjögren's syndrome (SjS), double-stranded DNA in systemic lupus 
erythematosus (SLE) and centromere-associated proteins in systemic sclerosis (SSc) are 
autoantigens recognized by disease-specific autoantibodies (Tan, 1989; Rahman et al., 2008; 
Nihtyanova et al., 2010). Thus, it is useful to find intracellular antigens and their 
autoantibodies for diagnosis, classification and to establish for criteria disease activity. 
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Fig. 1 Mechanisms for autoantibody production: apoptosis, antigen modification, and cross-
reactivity.  
 (A) Intracellular autoantigens are exposed into the extracellular environment, if clearance 
mechanisms are insufficient after apoptosis or necrosis. And then, these antigens may be 
recognized by B cells and autoantibody production. (B) Modification of intracellular proteins 
generates novel epitope, to which B cells have not been tolerized. (C) Autoantibody 
production arises from responses to foreign antigens, which cross-react with intracellular 
proteins. This figure was cited from the reference (Suurmond et al., 2015) 
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Screening method for discovering autoantigens 
Immunoprecipitation and expression screening from a cDNA library have been 
utilized as conventional method to discover autoantigens. However, in spite of both methods 
requiring tedious processes, non-specific results tend to be obtained, it is difficult to carry out 
a number of independent screenings, and the probability of success is low. 
As an alternative method, phage display using filamentous M13 phage was proposed 
in 1985 (Smith, 1985). This approach is based on two pivotal concepts. The first is that a 
protein or peptide is displayed on the surface of a phage particle and the genes encoding it are 
contained within the same particle. The second concept is that individual phages can be 
selected from large libraries by interaction of the displayed protein with a bindable probe, 
such as proteins, polysaccharides, lipids, nucleic acids and chemicals. Then, selected phages 
can be amplified by infecting bacteria. A phage display library is easier to make than a 
chemical library, may contain enormous diversity (more than 10
11
), and amino acids 
sequences can be determined with ease and precision by reading DNA sequences. Therefore, 
this technique was expected to work well for searching for autoantigens, but no cytoplasmic 
autoantigen has been reported using a phage display made with the M13 filamentous phage. 
This unexpected result is probably caused by the life cycle of M13 filamentous phage. In 
M13, foreign DNA product is fused to the N-terminal of the phage’s coat protein pIII. 
However, this fusion protein maintains its infectivity, and has to transfer into the periplasmic 
space across the inner membrane of the host E.coli cell, when phage assembly occurs (Fig. 2). 
Thus, proteins with low membrane permeability tend not to be displayed on the surface of 
phage. Besides, the environment in the periplasmic compartment is oxidizing, hence 
imprecise disulfide bonds possibly occur, resulting in a non-native conformation and function 
of the intracellular protein (Barbas et al., 2001). 
 
10 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Life cycle of M13 filamentous phage. This figure was cited from the reference ( 
Pacheco et al., 2012) 
 
To overcome this problem, Maruyama developed a novel bacteriophage lambda 
surface display vector, foo, in which a foreign protein is produced as a chimeric protein 
fused to the C-terminal phage coat protein D (Maruyama et al., 1994; Mikawa et al., 1996). It 
is expected that both secreting and intracellular proteins can be expressed while maintaining 
their native conformation and function, because a foreign protein does not need to pass 
through membrane when foo phage assembly occurs in the cytoplasm (Fig. 3). 
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Fig. 3 Life cycle of lambda phage. This figure was cited from the reference ( 
Feiner et al., 2015) 
 
Objective of this research 
With this new λ phage display system, I would like to demonstrate whether 
intracellular autoantigens can be selected from a cDNA library using the serum of 
autoimmune disease patients, and moreover to discover novel autoantigens, which is the first 
challenge. 
In chapter 1, as a model experiment, I explored the approach of affinity isolation of 
cDNA clones encoding intracellular autoantigens from HeLa and HepG2 cDNA libraries 
made with foo, using sera from patients with SjS. In chapter 2, I isolated novel autoantigens 
by using specimens from a patient with RA. 
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Chapter 1 
Affinity selection of cDNA libraries by  phage surface display 
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Summary 
 
  Bacteriophage  surface display was used to isolate cDNA clones encoding 
autoantigens recognized by sera from patients with Sjögren's syndrome. I made cDNA 
libraries from human HeLa and HepG2 cells, using an expression vector, foo. By repeating 
affinity selection of the libraries with the sera immobilized in microtiter wells, I isolated three 
clones that encode novel antigens as well as four clones previously known as SjS 
autoantigens. The newly identified autoantigens include TRK-fused gene product (TFG), 
survival motor neuron gene product (SMN) and pM5, which has a similarity to the metal-
binding domain of human fibroblast collagenase. Thus, the bacteriophage  surface display is 
powerful to isolate cDNA clones by affinity screening.  
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Introduction 
 
cDNA library screening requires tedious processes including preparation of a number 
of membrane filters blotted with approximately a million of bacterial colonies or 
bacteriophage plaques, which are subsequently searched for by using probes such as labeled 
proteins or DNA. In order to streamline the screening of cDNA libraries, Maruyama et al. 
have devised a bacteriophage lambda surface display vector, foo, in which a foreign protein 
is produced as a chimeric fusion protein to the phage coat proteins (Maruyama et al., 1994; 
Mikawa et al., 1996). Therefore, foo cDNA libraries can be screened by affinity 
chromatography with molecules immobilized on the surface of solid matrices including 
microtiter wells and agarose beads. Similar vectors based on  phage have also been 
developed (Sternberg and Hoess, 1995; Dunn, 1995; Santini et al., 1998), and many 
functional prokaryotic and eukaryotic proteins have been produced on the surface of the 
vector phage. The vectors have also been applied to mapping linear and conformational 
epitopes by affinity screening of random fragments of antigens expressed on the phage 
surface (Kuwabara et al., 1997; 1999; Moriki et al., 1999). In this chapter, I have further 
explored an approach to the affinity isolation of cDNA clones encoding autoantigens from 
HeLa and HepG2 cDNA libraries made with foo, using sera from patients with SjS as 
probes. Since many autoimmune sera recognize conformational epitopes of autoantigens, I 
may be able to test foo for its ability to express conformational epitopes on its surface and 
for affinity selection of such clones from complex libraries. 
  SjS is a chronic autoimmune disease characterized by lymphotic infiltrates of salivary 
and lachrymal glands with progressive destruction of the parenchymal tissue leading to a 
reduction or complete loss of secretory function. Sera from patients with SjS often contain 
autoantibodies reacting with nuclear and cytoplasmic components (Fayyaz et al., 2016). 
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Among them, anti-SS-B/La autoantibody is used as a diagnostic marker for SjS (Tan, 1989). 
The SS-B/La antigen, a 50 kDa protein, binds RNA polymerase III transcripts as part of their 
maturation process (Gottlieb and Steitz, 1989). In the present, anti-SS-A/Ro and anti-SS-B/La 
are used for diagnostic criteria; however, their sensitivity and specificity are not sufficient for 
the diagnostic of SjS. Although less frequently observed, SjS sera also recognize many other 
autoantigens including human replication protein A (RPA) (Garcia-Lozano et al., 1995), 
RNA polymerase I transcription factor hUBF/nucleolus organizer region autoantigen (NOR-
90) (Fujii et al., 1996), and the cell proliferation-associated protein Ki-67 antigen (Bloch et 
al., 1995). Meanwhile, many studies are carried out for the relationship between 
autoantibodies and clinical manifestation in SjS (Fayyaz et al., 2016). Therefore, novel sets of 
autoantigens and autoantibodies open a window for not only the diagnostic approach, but also 
the therapeutic method. 
  Isolation of autoantigens recognized by sera from patients with an autoimmune 
disease has been traditionally carried out through time-consuming processes by either 
immunoprecipitation of autoantigens, or immuno-screening of cDNA expression libraries 
constructed with plasmid or phage vectors. In this chapter, I describe an innovative approach, 
affinity screening of foo surface display libraries, to the isolation of cDNA clones encoding 
autoantigens recognized by SjS sera. Using sera from 51 patients with SjS as probes, I have 
screened HeLa and HepG2 cDNA libraries constructed with foo, and have found seven 
clones encoding three unknown and four known proteins as autoantigens. 
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Materials and Methods 
 
Bacteria, cell lines, phage vector and sera  
  The following Escherichia coli strains were used; JM105 (Yanisch-Perron et al., 
1985), TG1 (Mikawa et al., 1996), and Q447 (Kuwabara et al., 1999). The bacteriophage 
surface expression vector foo (Mikawa et al., 1996) was modified to accommodate two Sfi I 
recognition sites in its multiple cloning site in order to simplify the process of cDNA library 
construction (Christian et al., 1992). The following double-stranded synthetic 
oligonucleotides,  
 5'-GATCCCCGGGTACCGAGGCCGCCTCGGCCGAGCTCGAATTCGGCCGGCCATAGCGGCCGC 
      3'-GGGCCCATGGCTCCGGCGGAGCCGGCTCGAGCTTAAGCCGGCCGGTATCGCCGGCGTTAA, 
in which Sfi I recognition sequences are underlined, were inserted into foo DNA digested 
with Bam HI and Eco RI. The resulting vector was designated as foo2SfiI. Sera from 51 
patients with SjS were provided by Scripps Reference Laboratory, The Scripps Research 
Institute, La Jolla, CA, and used as probes for screening of cDNA libraries. The following 
sera were obtained from the laboratory serum bank of Nara Medical University, Nara, Japan; 
21 sera from patients with SjS, 8 sera from patients with systemic lupus erythematosus (SLE), 
8 sera from patients with primary biliary cirrhosis (PBC), 6 sera from patients with systemic 
sclerosis (SSc), and 72 sera from healthy people. Human cultured cell lines, HeLa and 
HepG2, obtained from American Type Culture Collection (Manassas, VA) were maintained 
in Dulbecco's modified eagle medium (DMEM; Life Technologies, Rockville, MD) 
supplemented with 10% (vol/vol) fetal calf serum (Life Technologies), 2 mM L-glutamine, 
100 units/ml penicillin-G and 100 µg/ml streptomycin sulfate in a 5% CO2/95% air incubator. 
 
cDNA library construction 
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  Total RNA was prepared from ~3 x 108 HeLa or HepG2 cells through standard 
procedures using guanidine thiocyanate treatment followed by CsCl centrifugation. From 
approximately one mg of the total RNA, poly(A)+ RNA, about 25 µg, was enriched by a 
single cycle of oligo(dT)-cellulose column chromatography as described previously 
(Sambrook et al., 1989). The first strand cDNA was synthesized from 5 µg of the poly(A)+ 
RNA using SuperScript II reverse transcriptase (Life Technologies) and 2.5 µg of random 
hexamers (Sigma, St. Louis, MO). The second strand of the cDNA was synthesized using a 
kit (Promega, Madison, WI) according to the manufacturer's protocol. Using T4 DNA ligase 
(New England Biolabs, Beverly, MA), the resulting double-stranded cDNA was ligated with 
the mixture of following Sfi I adaptors;  
  adaptor 1,  5'-CGGCCAGGATCTGGTGGT 
      3'-GGAGCCGGTCCTAGACCACCA 
and  adaptor 2,    5'-CTGACTGACTGAGGCCATAG 
      3'-GACTGACTGACTCCGGT. 
Unligated adaptor oligonucleotides were removed from cDNA by passing the ligation 
mixture through a Sephacryl S-400 (Amersham Pharmacia Biotech, Piscataway, NJ) spin 
column. The resulting cDNA was ligated with one µg of the foo2SfiI phage vector DNA 
digested with Sfi I. After incubating overnight at 16ºC, the ligation mixture was packaged 
using MaxPlax (Epicentre Technologies, Madison, WI), and was amplified by infection of 
the E. coli strain Q447. General procedures for the cDNA synthesis, adaptor ligation and 
phage DNA packaging were previously described (Ausubel et al., 1987). 
 
Affinity selection of cDNA library 
  Microtiter wells (Immulon 4; Dynatec Laboratory, Chantilly, VA) were coated 
overnight at 4°C with 50 µl of 20 µg/ml protein A (Sigma) in phosphate-buffered saline 
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(PBS; 137 mM NaCl/8.1 mM Na2HPO4/2.68 mM KCl/1.47 mM KH2PO4) containing 0.05% 
(wt/vol) sodium azide. After pre-blocking the wells with 50 µl of PBS containing 1.0% 
(wt/vol) bovine serum albumin (BSA) and 0.05% sodium azide, patient sera diluted 1/100 in 
PBS were added to the wells and incubated overnight at 4ºC in order to capture IgG to the 
wells. Unbound serum proteins were removed by washing the wells twice with blocking 
buffer [PBS/0.1% (vol/vol) Tween-20/0.25% BSA/5% (wt/vol) non-fat dry milk/0.1% 
sodium azide].  
  The cDNA libraries were grown with TG1, and after complete lysis the library phage 
was precipitated by the addition of 7% (wt/vol) polyethylene glycol (PEG; Mw, ~8000; 
Fisher, Fair Lawn, NJ), 0.6 M NaCl and 2 mM MgCl2 at final concentrations. After re-
suspending the phage precipitate in -dil (Maruyama et al., 1994), an aliquot, ~2 x 1010 pfu, 
was applied to the microtiter wells coated with patient sera, and incubated overnight at 4°C. 
Unbound phage was removed by washing the well three times with 200 µl of washing buffer 
(PBS/5% non-fat dry milk/0.5% Tween-20/0.1% sodium azide) for 5 min at room 
temperature, and then three times with 200 µl of dil for 5 min at room temperature. Bound 
phage to the well was eluted with 50 µl of collagenase solution [20 units collagenase (Sigma) 
in -dil supplemented with 10 mM CaCl2] for 2 h at 37°C. Phage titers were assayed as 
described previously (Sambrook et al., 1989). 
 
Phage culture, plaque staining and DNA sequencing 
  Phage was cultivated either in CY liquid medium (Maruyama et al., 1994) or on an E. 
coli lawn on an agar plate. General manipulation of phage was described previously 
(Sambrook et al., 1989). Immediately before the affinity selection, phage was cultured with a 
suppressor-positive strain, TG1. After affinity selection of cDNA libraries, an aliquot of 
eluted phages from the wells was infected JM105 and plated on agar containing 20 µg/ml 5-
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bromo-4-chloro-3-indolyl ß-D-galactoside (XGal) at a final concentration. The foo2SfiI 
vector phage formed a blue plaque while recombinant fusion phage formed a white plaque on 
the plate. Plaques formed on the plate were lifted onto a nitrocellulose filter (Shleicher & 
Schuell, Keene, NH) and stained with patient sera as previously described by Kuwabara et al. 
(1997). Phage particles picked from the plaque were directly used for DNA sequencing as 
described previously (Kuwabara et al., 1997).  
 
Phage ELISA 
  Microtiter wells were coated overnight at 4ºC with rabbit polyclonal anti-foo phage 
antibody (a gift from Taka Yamori, The Cancer Institute, Otsuka, Tokyo, Japan) at 2 µg/ml in 
PBS containing 0.05% sodium azide. Meanwhile, fusion phages were grown with TG1 until 
complete lysis in order to express foreign proteins on its particle surface. This phage culture 
was diluted 1/10 in ELISA buffer [PBS/5% non-fat dry milk/0.1% (vol/vol) Triton X-
100/0.1% sodium azide], and incubated overnight at 4ºC in the microtiter wells pre-blocked 
with PBS containing 1.0% BSA and 0.05% sodium azide. After washing the wells three times 
with ELISA buffer, patient sera diluted 1/1000 in PBS were bound to the wells for 1 h at 
room temperature. After washing the wells six times with ELISA buffer, secondary antibody, 
alkaline phosphatase-conjugated mouse anti-human IgG (Sigma) diluted 1/10,000 in PBS, 
was added to the wells and incubated for 1 h at room temperature. After the wells were 
washed four times with ELISA buffer and then twice with AP buffer (100 mM Tris-HCl, pH 
9.5/100 mM NaCl/5 mM MgCl2), a substrate for alkaline phosphatase, 2 mg/ml SIGMA-104 
in AP buffer, was added to the wells and incubated for 1 h at room temperature. Alkaline 
phosphatase activity captured to the wells was estimated by measuring optical densities (OD) 
at 405 nm using a microplate reader (Molecular Devices, Sunnyvale, CA). This measurement 
was repeated three times for a patient serum, using the vector phage as a negative control. 
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Patient sera were judged to have antibody reactive with autoantigens when the mean OD 
value was greater than 3 x S.D. (standard deviation) above the mean OD values of the 
negative control. 
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Results 
 
cDNA library construction 
  HeLa and HepG2 cDNA libraries constructed with foo consisted of 2.7 x 107 and 2.5 
x 107 plaque-forming units (pfu) of phages, of which 15.3% and 3.0% formed white plaques, 
respectively, on plates containing the color indicator XGal. The foo vector is designed to 
express peptide of E. coli -galactosidase (Gal) so that the vector phage forms a blue 
plaque on a lawn of E. coli expressing Gal peptides, such as the strain JM105, in the 
presence of XGal as a substrate for Gal. Insertion of cDNA into the cloning site of the 
vector prevent the expression of -peptide. Therefore, from phage plaque color I could 
estimate the pfu of recombinants with inserts in the cDNA libraries; 4.1 x 106 and 7.5 x 105 
pfu of recombinants in the HeLa and HepG2 libraries, respectively. However, a half of the 
recombinants should be in a reverse orientation, and two out of three clones should be out of 
reading frames. The libraries were, therefore, estimated to comprise of 6.9 x 105 and 1.3 x 
105 pfu selectable recombinants, respectively. The cDNA libraries were amplified by 
infection of an E. coli strain without an amber suppressor mutation to prevent the production 
of fusion proteins that might result in biased libraries. The vector is designed to accommodate 
the amber stop codon TAG between the phage coat protein gpD and a foreign protein 
encoded by inserted cDNA. Therefore, foreign proteins are produced on the surface of the 
phage particles as fusion proteins to the coat protein only when the phage is grown with E. 
coli hosts having an amber suppressor mutation, such as the strain TG1, immediately before 
affinity screening of cDNA libraries.  
 
cDNA library screening 
  I made nine mixtures from 51 sera from patients with SjS, in which five or six 
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different patient sera were mixed and used to select clones from the HepG2 cDNA library. 
For affinity selection, approximately 2 x 1010 pfu phages from the library grown with TG1 
were applied to microtiter wells coated with the serum mixtures. After extensive washing to 
remove unbound phages from the wells, bound phages were eluted by collagenase digestion. 
The vector is designed to have a collagenase recognition site between the coat protein gpD 
and a foreign fusion protein so that infectious phage particles can be released from the wells 
by the enzyme digestion. An aliquot, ~500 pfu, of the eluated phages was plated on agar, and 
phage plaques were immunostained with the serum mixtures after blotting onto nitrocellulose 
filters. The remaining eluates were amplified by growing with TG1 for subsequent affinity 
selection. After four rounds of affinity selection using the nine serum mixtures, five mixtures 
were found to enrich for immunoreactive clones. An example of such successful enrichment 
is shown in Fig. 4. As the selection cycles proceeded, the fraction of phages formed white 
plaques in total eluate phages was increased and the number of phage clones stained with the 
serum mixtures was also increased. I isolated ten serum-reactive clones from each of the 
second eluates of the five successful enrichment, and analyzed by PCR and DNA sequencing 
using primers that hybridize to the vector DNA. All the ten clones from each of the five 
successful selections contained inserts with the same size and nucleotide sequence. It was 
also found that a clone having the same insert was selected by two separate serum mixtures. 
Therefore, by this affinity selection four different clones were isolated and designated as 
Sg1p3, Sg3p11, Sg4p1 and Sg9p22 (Table 1). Using these isolated clones, individual serum 
in the serum mixtures was searched for and serum that specifically reacted with the clone was 
identified. 
  I also carried out affinity selection of the HeLa cDNA library, using 17 individual 
patient sera and eight mixtures consisting of four or five sera (34 sera in total) from different 
patients from the seventeen. From selection with the individual 17 sera, two positive clones 
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were isolated and designated as S7-1 and S12-11 after DNA sequencing analysis. By 
selection with the 8 mixtures, three were able to enrich for immunoreactive clones. Based on 
its DNA sequence, three different clones were isolated and designated as Sg2-1, Sg4-1 and 
Sg7-2. These results are summarized in Table 1.  
 
DNA sequence analysis of isolated clones 
  Nucleotide sequences of the 5' and 3' ends of the cDNA inserts of the isolated phage 
clones, >400 nucleotide bases long from both of the boundaries, were compared with 
sequences in databases, GenBank, EMBL, DDBJ and PDB, using the BLAST software 
(Altschul et al., 1990). All the clones encoded a portion of seven known proteins (Fig. 5). 
Among the seven, three clones, Sg7-2, Sg3p11 and Sg4-1, have not previously been reported 
as autoantigens in any autoimmune diseases while the other four, Sg1p3, Sg2-1, Sg9p22 and 
S7-1, have been characterized as autoantigens recognized by sera from patients with SjS. 
Sg7-2 coded for a central portion of a survival motor neuron gene product (SMN), which is 
also known as a product of spinal muscular atrophy (SMA)-determining gene (Lefebvre et al., 
1995). Sg3p11 encoded the carboxyl-terminal portion of the pM5 protein and its 3' 
untranslated region, which was previously isolated from an A2058 melanoma cDNA library 
using probes that have homology to the metal-binding domain of human fibroblast 
collagenase (Templeton et al., 1992). The clones Sg4-1 and Sg4p1 encoded the amino-
terminal regions of TRK-fused gene (TFG), which is fused to the 3' end of NTRK1 (one of 
the receptors for nerve growth factor), generating the TRK-T3 fusion transcript found in 
papillary thyroid carcinoma (Greco et al., 1995). 
  The clones Sg1p3 and S12-11 encoded the amino-terminal regions of SS-B/La, which 
is a ribonucleoprotein in association with RNA polymerase III transcripts (Gottlieb and Steitz, 
1989). Autoantibodies to SS-B/La are often found in sera of patients with autoimmune 
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diseases, SjS and SLE. The clone Sg2-1 encoded the amino-terminal 1/3 of the 70-kDa 
subunit of human replication protein-A (hRPA-70), which is a highly conserved protein 
complex with single-stranded DNA binding activity (Erdile et al., 1991). Sg9p22 encoded a 
portion of nucleolus organizer region-90 / human upstream binding factor (NOR-90/hUBF), 
which activates RNA polymerase I-mediated ribosomal RNA transcription (Chan et al., 
1991). S7-1 encoded the carboxyl-terminal region of the cell proliferation-associated protein 
Ki-67 antigen, one of the ribonucleoprotein involved in cell cycle. Antibody against the Ki-
67 antigen is used as a 'proliferation marker' to measure the growth fraction of cells in human 
tumors (Gerdes et al., 1983). 
 
Frequency of patient sera that recognize isolated autoantigens 
  To investigate the frequency of the presence of autoantibodies against the isolated 
antigens in autoimmune sera as well as in normal sera, I used the phage clones to detect 
autoantibodies in sera from 72 patients with SjS, 22 with other autoimmune diseases (8 SLE, 
8 PBC and 6 SSc) and 72 sera from healthy people by enzyme-linked immunosorbent assay 
(ELISA; Engvall and Perlmann, 1971) using the phage clones as described in Materials and 
methods. As shown in Table 2, Sg1p3 (SS-B/La) reacted with 21 out of 72 SjS sera (29%) 
and one PBC serum out of 22 sera from other autoimmune sera (4.5%). The 21 positive sera 
include all of 20 sera shown to have anti-SS-B/La antibodies based on immunodiffusion 
precipitin reaction and ELISA. This attests that phage ELISA is as sensitive as the 
conventional methods. The Sg2-1/hRPA-70 clone reacted with 2 out of 72 SjS sera (2.8%) 
and 2 out of 8 SLE sera (25%). Four sera out of 72 SjS sera reacted with Sg7-2/SMN clone 
(5.5%), and one serum out of 22 other autoimmune sera (4.5%) or one out of six SSc (16.7%). 
Sg3p11 coding for pM5 reacted with 3 sera from patients with SjS (4.2%), but not with other 
autoimmune sera. Three other clones (Sg9p22/NOR-90, S7-1/Ki-67 antigen and Sg4-1/TFG) 
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reacted with only one of 72 SjS sera (1.4%) and with none of 22 other autoimmune sera. 
Among 72 normal sera examined, only one serum reacted with Sg4-1/TFG, and none reacted 
with the other clones. 
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Discussion 
 
  In this study using the foo phage display, I have successfully isolated cDNA clones 
that encode seven different autoantigens recognized by SjS sera from HeLa and HepG2 
libraries; three proteins, SMN, pM5 and TFG, previously not known as autoantigens, and 
four proteins, SS-B/La, hRPA-70, NOR-90 and Ki-67 antigen, previously identified as SjS 
autoantigens. However, the TFG clones Sg4-1 and Sg4p1 were also recognized by serum 
from a healthy person, and therefore the autoantigen appears not to be specific to SjS. SS-
B/La is one of the major target antigens recognized by sera from patients with SjS. The 
clones Sg1p3 and S12-11 encoded the amino-terminal regions of SS-B/La and the shorter 
clone Sg1p3 reacted with all the sera tested that contain anti-SS-B/La antibody. This result 
suggests that the major epitope recognized by sera from patients with SjS resides in the 
amino-terminal region of SS-B/La. The result is consistent with that from epitope mapping by 
McNeilage et al. (1992), in which a major epitope has been mapped within the first 107 
amino-terminal residues as a discontinuous epitope. Nyman et al. (1989) also have mapped 
an epitope site in the amino-terminal region, while Bini et al. (1990) determined two epitope 
sites, one each in the amino- and carboxyl-terminal halves of the protein.  
  RPA consists of three subunits of 70, 32 and 14 kDa and seems to function in both the 
initiation and elongation stages of DNA replication (Sibenaller et al., 1998). Recently, using 
immunoblot analysis, it has been demonstrated that two (70 and 32 kDa) of these subunits 
react with sera from SjS and SLE patients (Garcia-Lozano et al., 1995, 1996, Yamasaki et al., 
2006). Sg2-1 encoding the first 186 amino-terminal residues of hRPA-70 reacted with two 
sera out of 72 (2.8%) from patients with SjS and two sera out of eight (25%) from patients 
with SLE. It has also been estimated that the frequency of antibodies against the RPA 
subunits in sera from patients with SjS is 2-3% (Garcia-Lozano et al., 1995, Yamasaki et al., 
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2006), which is consistent with our results. No epitope site in hRPA-70 recognized by SjS 
sera has been previously analyzed, except for the region, 1-186 amino acid residues, of 
hRPA-70 encoded by the clone Sg2-1 isolated in this work. NOR-90 has previously been 
characterized as autoantigens recognized by SjS sera, and autoantibody against NOR-90 has 
been observed in approximately 7.7% and 2.2% of sera from patients with SjS and SSc, 
respectively (Fujii et al., 1996). Major epitopes on the NOR-90 molecule have been mapped 
to two regions encompassing residues 89-310 and 310-633. The clone Sg9p22 encoded a 
smaller region, amino acid residues 433-510, of NOR-90, which overlapped with one of the 
epitope regions described above. In the present study, the phage clone Sg9p22 was 
recognized by 1.4%, one out of 72, of sera tested. This is significantly lower than the 
frequency observed previously and probably due to the lack of the second epitope site in the 
clone Sg9p22. The Ki-67 antigen has been found as an autoantigen by screening a gt11 
HepG2 cDNA library with serum from a patient with SjS (Bloch et al., 1995). The isolated 
cDNA clone encoded amino acid residues 1159-1526 of the Ki-67 antigen, which is far apart 
from the region, 2823-2916, encoded by the clone S7-1 in this study. These results suggest 
that at least two epitope sites on the Ki-67 antigen are recognized by SjS patient sera.  
  Thus, cDNA expression libraries made with the foo vector are powerful tools to 
identify cDNA clones encoding autoantigens using sera from patients with autoimmune 
diseases as probes. The technique requires only less than five µl of sera from patients, and 
many independent screenings can be simultaneously carried out using a microtiter plate 
coated with many sera from different patients. Phage ELISA described in this chapter is as 
sensitive as conventional methods such as ELISA and immunodiffusion precipitin reaction. It 
may also be efficient for the detection of autoantibodies against autoantigens in patient sera, 
since the method does not require purified autoantigens. However, bacteriophage expression 
vectors including foo, gt 11 and ZAP may not be efficient for epitopes that are post-
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translationally modified by such a mechanism as glycosylation or phosphorylation. 
  In this cDNA library screening, I have successfully isolated at least two clones, Sg1p3 
and S12-11 that encode a conformational epitope recognized by SjS patient sera. This 
particular epitope of SS-B/La has previously been demonstrated to be conformational 
(McNeilage et al., 1992). Similarly, a large domain encoding a conformational epitope of 
human blood coagulation factor VIII has also been expressed on the surface of foo and 
recognized by conformation-specific antibodies (Kuwabara et al., 1999). Using lactose as a 
ligand, a domain of human galectin-3 required for the ligand recognition has been mapped by 
affinity selection of foo libraries (Moriki et al., 1999). Furthermore, many proteins have 
previously been produced with function on the surface of the foo vector phage; E. coli -
galactosidase and plant Bauhinia purpurea agglutinin (Maruyama et al., 1994). These results 
indicate that many proteins expressed on the surface of the vector phage retain their native 
conformation and function. Therefore, cDNA libraries constructed with foo may also 
efficiently be searched for proteins physically interacting with macromolecules including 
protein, DNA, RNA and polysaccharide immobilized on the surface of solid matrices such as 
microtiter wells or agarose beads. 
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Conclusion 
 
 In this study using the lambda phage display, I have successfully isolated that encode 
seven different autoantigens recognized by SjS sera from HeLa and HepG2 libraries; 
including previously identified as SjS autoantigens, and also novel antigens. The affinity 
selection using the phage display requires only a small amount, less than five microliter of 
patient’s serum. Furthermore, using a microtiter plate, many sera can simultaneously be used 
for the screening. Therefore, the approach employed in this work may be an economical and 
efficient alternative to the conventional approaches to the isolation of cDNA clones encoding 
autoantigens recognized by sera from patients with not only SjS but also other autoimmune 
diseases. 
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Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Affinity selection of cDNA libraries with sera from patients with SjS. Phages from the 
HepG2 cDNA library (Input; ~2 x 1010 pfu, 3% of which formed white plaques) were applied 
to a microtiter well coated with serum from a patient with SjS, and selected four cycles by 
affinity selection as described in Materials and methods. After each round of affinity 
selection, an aliquot of phage eluates was plated with bacteria to assay the fraction of white 
plaques in total plaques and the number of reactive clones with the patient serum used for the 
selection. The rest of the eluate was amplified by growing with bacteria for subsequent 
selection. In this figure, an example of such affinity selection is shown, and the increased 
fraction of white plaques in total phage plaques is illustrated by a line graph and the increased 
fraction of reactive clones with a patient serum in the library population by a histogram. 
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Fig. 5 cDNA sequences encoded by phage clones isolated. The 5'- and 3'-ends of cDNA 
inserts were determined by DNA sequencing using two oligonucleotide primers that 
hybridize to the vector DNA. At least 400 nucleotide bases were determined from both of the 
boundaries. Insert sizes of the clones were also confirmed by PCR. Rectangles indicate 
coding sequences of autoantigen cDNA based on published sequences. Lines protruded from 
the rectangles indicate the 5' and 3' untranslated regions on the left and right, respectively. 
DNA sequences encoded by all the cDNA clones isolated in this study are indicated by lines 
under the rectangles. The numbers of amino acid residues encoded by the autoantigen cDNA 
are shown inside the rectangles. The names autoantigens and isolated clones are shown on the 
left. 
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 Table 1  
 Summary of cDNA library screening 
 ________________________________________________________ 
 SjS sera          cDNA library       Clones isolated 
 ________________________________________________________ 
 Mixed    HepG2          Sg1p3 
 (9 groups/51 sera)      Sg3p11 
         Sg4p1 
         Sg9p22 
 
 Individual   HeLa     S7-1 
 (17 sera)        S12-11 
 
 Mixed    HeLa     Sg2-1 
 (8 groups/34 sera)       Sg4-1 
          Sg7-2 
 ________________________________________________________ 
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 Table 2  
 Frequency of antibodies against autoantigens in normal sera and sera from patients  
 with SjS and other autoimmune diseases. 
 ___________________________________________________________________ 
       Sera from patients with      
     ______________________________________________ 
 Clones
a
 (antigen)      SjS         Other autoimmune   Normal 
         
(%)
            
disease, (%)     (%) 
 
 ___________________________________________________________________ 
 Sg7-2 (SMN)  4/72 (5.5)  1/22 (4.5)  0/72 (0) 
 Sg3p11 (pM5)  3/72 (4.2)  0/22 (0)  0/72 (0) 
 Sg4-1 (TFG)b  1/72 (1.4)  0/22 (0)  1/72 (1.4) 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -   
 Sg1p3 (SS-B/La)b  21/72 (29)  1/22 (4.5)  0/72 (0) 
 Sg2-1 (hRPA-70)  2/72 (2.8)  2/22 (9.1)  0/72 (0) 
 Sg9p22 (NOR-90) 1/72 (1.4)  0/22 (0)  0/72 (0) 
 S7-1 (Ki-67 antigen) 1/72 (1.4)  0/22 (0)  0/72 (0) 
 ___________________________________________________________________ 
 aThree clones above the dotted line encode previously unknown proteins as  
 autoantigens and four clones below the line encode SjS autoantigens previously known. 
 bThe same results were obtained for the clones Sg4-1 and Sg4p1, and for Sg1p3  
 and S12-11. 
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Chapter 2 
 
Novel Autoantigens Recognized by Sera and Synovial Fluids from Patients with 
Rheumatoid Arthritis: Isolation by Using Bacteriophage  Surface Display 
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Summary 
 
To isolate cDNA clones encoding novel autoantigens recognized by sera or synovial 
fluids (SFs) from patients with RA, I constructed cDNA libraries from synovial sarcoma cells 
as well as from synovial tissues, using a surface-display vector, foo. The libraries were 
screened by affinity selection using 48 sera and 40 SFs from RA patients as probes 
immobilized in microtiter wells. As a result, 13 different autoantigens were isolated. These 
include seven proteins previously known to be recognized by RA sera, two proteins 
previously unknown to be recognized by RA sera, and four novel autoantigens that are 
previously unanalyzed in any autoimmune diseases, including an unknown protein. 
Frequencies of sera that recognize these novel autoantigens were ranged from 12.5 to 24.0% 
of a panel of RA sera, and 0 to 4.2% of other rheumatic disease sera. The novel autoantigens 
may serve as diagnostic and prognostic markers for RA as well as for understanding etiology 
and pathogenesis of RA. 
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Introduction 
 
RA is characterized by chronic polyarthritis and destruction of multiple joints. 
Although etiology of RA is not yet known, a number of autoantibodies have been identified 
in sera from patients with RA, and antigen-driven immune response has been suggested 
(Smolen et al., 1998; von Landenberg et al., 2000). Despite many serum antibodies identified 
in RA, rheumatoid factors (RF), which are detected in ~80% of the patients, remain the main 
serological marker of the disease. Other serum antibodies with high sensitivity and specificity 
for RA include antibodies against filaggrin (also called antiperinuclear factor, anti-rat 
esophagus or anti-keratin antibodies), collagen, Sa, A2/RA33, 68-kd protein and 
gp130/follistatin-related protein (Le Goff et al., 1997; Blass et al., 1995; Tanaka et al., 1998). 
However, no single marker with sufficient sensitivity and specificity for the diagnosis of RA 
is currently available. Identification of sensitive and specific markers for RA that are present 
early in the course of the disease is also receiving considerable attention (Le Goff et al., 
1997). 
Isolation of autoantigens recognized by sera from patients with autoimmune diseases 
has been traditionally carried out through time-consuming processes by either 
immunoprecipitation of autoantigens or by immuno-screening of cDNA expression libraries 
constructed with plasmid or phage vectors. To identify autoantigens more efficiently, 
Maruyama et al. have developed a surface display vector based upon bacteriophage lambda, 
in which an antigen protein encoded by cDNA is produced as a chimeric fusion to the phage 
coat proteins (Maruyama et al., 1994; Mikawa et al., 1996). Libraries constructed with the 
vectors can be searched for clones of interest by simultaneously using many different probes 
immobilized with beads or in microtiter wells (Kuwabara et al., 1997; Moriki et al., 1999).  
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In this chapter, I describe the application of the lambda phage surface display to the 
isolation of autoantigens by using RA patient SF and sera as probes. Using 48 sera and 40 SF 
from RA patients as probes, I have screened synovial tissue and synovial sarcoma cell line, 
SW982 cDNA libraries constructed with foo, and have found four novel autoantigens that 
are previously unanalyzed in any autoimmune diseases, including an unknown protein. 
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Materials and Methods 
 
Tissue, cell lines and sera  
Synovial tissue from RA patients was provided from Nara Medical University, Nara, 
Japan. Human synovial sarcoma cell line, SW982, was obtained from American Type Culture 
Collection (Manassas, VA), and maintained in Leibovits’-15 medium (Life Technologies, 
Rockville, MD) supplemented with 10% (vol/vol) fetal calf serum (Life Technologies), 2 mM 
L-glutamine, 100 units/ml penicillin-G and 100 µg/ml streptomycin sulfate in an air incubator 
in the absence of added CO2. Sera and SF from patients with RA were provided by Scripps 
Reference Laboratory, The Scripps Research Institute, La Jolla, California, and by the 
laboratory serum bank of Nara Medical University. The following sera were also from Nara 
Medical University; SLE, SjS, SSc, mixed connective tissue disease (MCTD), osteoarthritis 
(OA) and sera from healthy persons. Diagnoses were made according to a review of clinical 
charts and information from the attending physicians, and were based on American College 
of Rheumatology criteria and on SjS classification criteria. 
 
cDNA library construction 
Total RNA was prepared from 3 g of synovial tissue from RA patients or ~10
8
 
SW982 cells by using an RNeasy kit (Qiagen, Valencia, CA), according to the manufacture’s 
protocol. General procedures for poly(A)
+
 RNA preparation, cDNA library construction were 
as previously described in chapter 1. Synovial tissue and SW982 cDNA libraries consisted of 
3.3 x 10
6
 and 1.5 x 10
7
 pfu of recombinants with cDNA inserts, respectively, when analyzed 
by PCR.  
 
Affinity selection of cDNA library  
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Detailed procedures for affinity selection of the phage libraries were previously 
described in chapter 1. As probes, patient sera or SF were used after diluted to 1/1000 with 
PBS and immobilized in microtiter wells. To remove RF from sera or SF prior to 
immobilization, 20 µl immunoglobulin-G (IgG)-agarose (9.8 mg protein/ml resin; Sigma, St. 
Louis, MO) was added to the diluted sera or SF and incubated with mild agitation for 16 h in 
a cold room. Furthermore, to prevent interaction between RF and cDNA clones expressing 
the Fc domain of IgG, 0.5 µl of recombinant human IgG-Fc protein (12 mg/ml; ICN 
Pharmaceuticals, Aurora, OH) was added to binding buffer. 
 
Analysis of phage clones 
Procedures for phage plaque staining, plaque hybridization, DNA sequencing of 
cDNA inserts were previously described in chapter 1. 
  
Phage ELISA  
ELISA was carried out by using phage particles expressing antigen proteins on the 
surface. This method called ‘phage ELISA’ has proved to be as sensitive and specific as 
ELISA using purified antigen proteins in chapter 1. Detailed procedures for phage ELISA 
were as previously described in chapter 1. Positive sera were determined when the values 
were higher than 3 x SD of reference sera. 
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Results 
 
cDNA library screening 
 I constructed a cDNA library from synovial tissues of patients with RA, which is a 
primary target of T- and B-lymphocytes in RA. Using 48 sera and 40 SF from RA patients as 
probes, the synovial tissue cDNA library was searched for antigens. After two to four 
selection cycles, most of the sera and SF enriched for cDNA clones encoding the Fc fragment 
of IgG. This is not surprising because synovial tissues from RA patients become infiltrated by 
lymphocytes and because most of sera and SF from RA patients contain RF. Therefore, I 
treated the sera and SF with IgG-agarose beads to remove RF before immobilizing in 
microtiter wells. During the affinity selection, purified human IgG-Fc proteins were also 
added to binding buffer in order to inhibit interaction between RF and cDNA clones encoding 
Fc. By these treatments, the enrichment of the Fc clones was dramatically decreased to less 
than 1% of that without the treatment. This improved approach allowed us to isolate five 
different cDNA clones encoding two proteins previously unknown to be recognized by RA 
sera, type-1 nuclear mitotic apparatus protein (NuMA1) and muscle myosin heavy chain, and 
three proteins known to be recognized by RA sera, branched chain 2-oxo-acid dehydrogenase 
complex-E2 (BCOADC-E2), La/SSB and IgG (Table 3). These proteins have previously been 
analyzed as autoantigens in other autoimmune diseases; NuMA1 in SLE (Andrade et al., 
1996), myosin heavy chain in acute rheumatic fever (Horsfall et al., 1992), BCOADC-E2 in 
PBC (Miyakawa et al., 1999), La/SSB in SjS (Tan, 1989), and IgG in RA and other 
autoimmune diseases (Smolen et al., 1998). 
 To eliminate cDNA clones derived from lymphocytes, I also constructed a cDNA 
library from SW982 cells. Using 44 sera and 22 SF, I performed a single-cycle affinity 
selection, by which preferential enrichment for abundant cDNA clones with higher affinity 
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for autoantibodies may be minimized. This selection allowed us to isolate eight different 
clones; a clone encoding an unknown protein, three clones encoding previously unknown to 
be recognized by RA sera and four clones known to be recognized by RA sera (Table 3). 
DNA sequence analysis revealed that the clone Fw29a1 (GenBank accession no. AY557618) 
encodes an unknown protein matched with a genomic sequence on chromosomes X (Fig. 6). 
Three proteins, insulin-like growth factor binding protein-4 (IGFBP-4) (Matsumoto et al., 
1996) and sorcin (Maki et al., 2002), small humanin like peptide-1 (SHLP-1) (Cobb et al., 
2016) encoded by Nw8a1, Sw28b1 and Fw24d2, respectively, have not previously been 
reported as autoantigens in any autoimmune diseases. The other four clones encoded proteins 
previously known to be recognized by RA sera and other autoimmune sera with higher 
frequencies; PDC-E2 in primary biliary cirrhosis (Jones, 2000), CENP-B in SLE (Russo et al., 
2000), and 52- and 60-kd Ro/SSA in SjS (Lopez-Longo et al., 1994). 
 
Sensitivity and specificity of isolated autoantigens for RA 
 Among the 13 different antigens isolated, four had not previously been analyzed for 
their sensitivity and specificity for RA. Using panels of sera from 48 healthy persons and 48 
patients with RA or other rheumatic diseases (16 SJS, 16 SLE, 9 SSc, 3 MCTD, and 4 OA), I 
measured frequencies of the novel antigens recognized by the panels. Frequencies of sera that 
recognize the novel four autoantigens encoded by Fw24d2, Sw28b1, Nw8a1, and Fw29a1, 
were ranged from 12.5 to 24.0% of a panel of RA sera, and 0 to 4.2% of other rheumatic 
disease sera. Interestingly, each of these novel autoantigens has higher frequencies by sera 
from RA patients than by sera from healthy persons or patients with other rheumatic diseases 
(Table 4). 
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Discussion 
 
In this study using the lambda phage display, I have successfully isolated cDNA 
clones that encode novel autoantigens recognized by sera from patients with RA. Each of 
these novel autoantigens has higher frequencies by sera from RA patients than by sera from 
healthy persons or patients with other rheumatic diseases, but the sensitivity of these antigens 
are not as high as to substitute for RF, which is using as a maker for RA in criteria. However, 
possibilities remain that these novel antigens may use for activity markers or complementary 
markers of RF. 
One of the cDNA clones that encode novel autoantigens, encodes a 20/24 amino acid 
polypeptide of SHLP-1, which is a member of the family of small humanin-like peptides 
(SHLPs) (Cobb et al., 2016). Among the SHLP family, humanin is known as a potent 
neuroprotective factor (Hashimoto 2001), but the function of SHLP-1 is still unclear. 
Humanin and SHLP-2 are reported to be decreased in age-related diseases, such as 
Alzheimer’s disease and RA (Cobb et al., 2016). I speculate that the autoantibody against 
SHLP may reduce SHLP in sera from RA. 
Another clone encodes sorcin, which is a penta-EF hand calcium binding protein, 
which participates in the regulation of calcium homeostasis in cells. Sorcin regulates 
concentration of calcium ion in the endoplasmic reticulum (ER), allows high levels of 
calcium in the ER to be maintained, preventing ER stress (Colotti et al., 2014). It is not clear 
why the autoantibody against sorcin is produced, and the involvement with pathological 
condition. However, it has been reported that Calnexin, BiP and Grp94 which are calcium 
binding chaperones in ER, were identified as novel autoantigens in RA and SLE (Weber et al., 
2010). Thus, ER-residential calcium binding protein may raise an autoantibody in RA. 
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Among the novel antigens isolated, IGFBP-4 is of particular interest. Although 
sensitivity of this antigen is not high, its specificity is very high, and none of sera from other 
rheumatic diseases and healthy persons recognize the antigen. IGFBP-4 is a potent inhibitor 
of IGF actions in bone cells (Schiltz et al., 1993, Zhou et al., 2003), which is the most 
abundant growth factors produced by bone cells and stimulate both bone-cell proliferation 
and differentiation (Rosen et al., 1994). However, inhibitor action of IGFBP-4 is reassessed 
because IGFBP-4 knockout mice result in a reduction in body mass (Conover, 2008). The 
interpretation of these findings is that IGFBP-4 play a role as a reservoir for IGF. The 
bioactive IGF is released from this reservoir by IGFBP-4 specific protease (Durham et al., 
1995). On the other hand, it is reported that a concentration of IGFBP-4 is dramatically 
increased in RA SF (Matsumoto et al., 1995). The increase of IGFBP-4 in RA SF may be 
partly due to the antibodies specific to the antigen that may protect a cleavage site by the 
protease. Thus, specific antibodies to IGFBP-4 detected in sera from RA patients may partly 
explain RA pathogenesis. 
Despite isolation of many cDNA clones encoding antigens recognized by RA sera, I 
have failed to isolate many other clones encoding proteins previously identified as 
autoantigens with higher sensitivity and/or specificity for RA, such as filaggrin and collagen. 
If the specificity of antiperinuclear factor and antikeratin antibodies is directed to citrulline, 
an amino acid derived by citrullination of arginine and present in large quantities in 
epidermal filaggrin (Smolen et al., 1998), it may be difficult to isolate cDNA clones encoding 
filaggrin through the bacteriophage display.  
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Conclusion 
 
 In this study using the lambda phage display, I have successfully discovered four 
novel autoantigens that have not previously been reported as autoantigens in any autoimmune 
diseases. Besides, it was revealed that these novel autoantigens are specific for RA. However 
their specificity for RA is very high, sensitivity of these antigens are not high to substitute for 
RA in criteria. The approach employed in this work may be an economical and efficient 
alternative to the conventional approaches to the isolation of cDNA clones encoding 
autoantigens, more screenings for novel antigens are needed to discover a better marker of 
RA than RF. 
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Figure and Tables 
 
 
 
Fw29a1 
 
TTTAAGACTGACGTTAGTAACCCAGCTCAGAACAGGACCAGAGGGATGGACCGGGATGAC 
PheLysThrAspValSerAsnProAlaGlnAsnArgThrArgGlyMetAspArgAspAsp 
 
AGGAAAACTGGAACTTGTGTAACAGACACTAAAAAAACTAGGTGTCAGCGTTTTCTGGAA 
ArgLysThrGlyThrCysValThrAspThrLysLysThrArgCysGlnArgPheLeuGlu 
 
GAGGAACTCTGGGTGGAATGATCAGTGTGTAACAGGATATAAAAATGGAAGCTTCTACAG 
GluGluLeuTrpValGluSTOP (46 a.a.) 
 
AGACACTGAGCTACAATAAATGTGAAATTTCAGAGTCAGGTGCCAAATCGCCATATATAG 
ATTTACAAAAGAAATGGTTCCCGGGCCTGTTCAGCGACTCTGGAGGGTCTCAGCCAGATC 
AAAGATAGGAAAGGTCAGAGAGCGAGAAAGGGGAAATAGAGGAAGAGATTTAGGGGGAAG 
GGGTAGTAGCTGTGGTGTCTAAGACCCCACCCAAGCCCTTAAAATGAAAGGTTATATGGG 
GAAGGATGTATGTGGGAAGGTTTTACCTCTTAACCAAAGTCTAATGAGGGATCCGTCTGA 
GCCTGTCTCCTCACCCCCACTCTCCCTACCCTGGCCCTCAAAGGAGGGCTTCTTTACAGT 
TAATTGATTTCTTGGAATGGTCCCAAGGGAC (571 bp)  
 
 
Fig. 6  Nucleotide sequence of a cDNA insert of a clone, Fw29a1, which encodes a novel 
protein. Its amino acid sequence was also deduced and shown underneath the nucleotide 
sequence. 
 
  
46 
 
 
Table 3 
 
Summary of cDNA clones isolated 
cDNA lib. Clone  Insert size, bp       Antigen  Coding region 
a 
           
Synovial tissue 
  Previously unknown to be recognized by RA sera 
   RA123  701        NuMA1  627
th
-859
th
 
   RA128 
b
 347  Myosin heavy chain 75
th
-189
th 
  
Known to be recognized by RA sera 
   RA114  392        BCOADC-E2 136
th
-255
th
 
   RA143  968        La/SSB  1
st
-314
th
 
   RA4  737        IgG  253
rd
-473
rd
 
SW982 cell 
  Unknown protein 
   Fw29a1 
b
 571   on chromosome X 46 a.a. 
  Previously unknown to be recognized by RA sera 
   Fw24d2 
b
 60        SHLP-1  5
th
-24
th
 
   Nw8a1  354        IGFBP-4  7
th
-124
th
 
   Sw28b1 480        Sorcin  7
th
-167
th
 
  Known to be recognized by RA sera 
   Fw19a1 
b
 681        PDC-E2  50
th
-276
th
 
   Sw8b1  453        CENP-B  464
th
-599
th
 
   Sw17j1 1735        60-kd Ro/SSA 1
st
-554
th
 
   Sw17k1 665        52-kd Ro/SSA 1
st
-215
th
 
a
 Protein fragments encoded by cDNA inserts that are indicated by position of the first and 
last amino acid (a.a.) residues or length for an unknown protein encoded by Fw29a1. 
b
 Isolated by using SF from RA patients. 
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Table 4 
 
Sensitivity and specificity of autoantigens for RA 
 
 
Clone  Antigen   Sera 
a
 from patients with 
      __________________________________________ 
 
      RA (%) Other RD (%)  Healthy control 
(%) 
 
 
Sw28b1 Sorcin   7/48 (14.9)    1/48 (2.1)  0/48 (0) 
 
Nw8a1  IGFBP-4  6/48 (12.5)    0/48 (0)  0/48 (0) 
 
Fw24d2 SHLP-1  6/25 (24.0)    0/48 (0)  not tested 
 
Fw29a1 unknown  9/44 (18.8)    2/48 (4.2)   0/48 (0) 
 
a
 Sera from patients with RA or other rheumatic diseases (RD) were provided by the  
 
laboratory serum bank of Nara Medical University, Nara, Japan, and the Reference  
 
Laboratory, Scripps Research Institute, La Jolla, CA.  
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General Discussion 
 
In this study using the foo phage display technology, I have successfully isolated 
cDNA clones encoding many cytoplasmic autoantigens recognized by sera or SF from 
patients with SjS or RA. 
  In chapter-1; I isolated seven phages encoding four proteins previously identified as 
SjS autoantigens, namely SS-B/La, hRPA-70, NOR-90, and Ki-67 antigen, and three proteins, 
SMN, pM5, and TFG, previously not known as autoantigens in any autoimmune disease. 
Regarding the four proteins previously known as SjS autoantigens, two clones 
encoded epitopes of SS-B/La or NOR-90 previously found by SjS patient sera and the other 
two clones encoded novel epitopes of RPA-70 or Ki-67. These clones expressed polypeptides 
of a certain length, not short peptides (less than 20 amino acids length), so that these epitopes 
may be conformational epitopes. Actually, an epitope of SS-B/La has previously been 
demonstrated to be conformational (McNeilage et al., 1992) and that epitope is consistent 
with the region found in this study. Furthermore, many proteins have previously been 
produced that display their function on the surface of the foo phage. Therefore, it is 
suggested that many proteins expressed on the surface of the foo phage retain their native 
conformation and function. 
I also isolated phages expressing three novel autoantigens, SMN, pM5, and TFG, 
previously not known as autoantigens in any autoimmune disease. The clone encoding the 
amino-terminal region of TFG only reacted with one serum from a healthy donor and appears 
not to be a disease autoantigen. The other two clones, encoding SMN and pM5, reacted with 
more than one SjS serum, however, but not with any serum from healthy donor, so these two 
proteins may be novel specific autoantigens in SjS. 
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pM5, also known as nodal modulator 1, was previously isolated from an A2058 
melanoma, but the function of pM5 is still not understood well. The survival motor neuron 
gene product (SMN), which is known as the product of a spinal muscular atrophy (SMA)-
determining gene (Lefebvre et al., 1995), is expressed ubiquitously in all cell types, and is 
found in both cytoplasm and the nucleus. It has been reported that SMN forms 
macromolecular complexes, termed SMN complex, that are involved in the assembly of small 
nuclear ribonucleoprotein complexes (snRNPs). This snRNP is known as an autoantigen 
against anti-Sm autoantibody, one of the represented anti-nuclear autoantibodies detected in 
SLE. It has often been reported that antibodies are induced against each component of 
complex proteins, thus the anti-SMN antibody may be a novel anti-nuclear antibody, 
produced together with the production of anti-Sm autoantibody. 
 In chapter-2; I have successfully isolated cDNA clones that encode novel 
autoantigens recognized by SF or sera from patients with RA. 
L. J. Cobb et al. revealed new small mRNAs transcribed from mitochondrial DNA 
and named small humanin-like peptides (SHLPs) (Cobb et al., 2016). Humanin is composed 
of 24 amino acids, and is the best-characterized potent neuroprotective factor known to be a 
therapeutic agent for Alzheimer’s disease (Hashimoto 2001). SHLP-1 is a member of the 
family of these small mitochondria-derived peptides, a 24 amino acid polypeptide. SHLP-1 is 
expressed at a relatively high level in the heart, kidney, and spleen. However, although 
SHLP-2 and -3 are known to share similar protective effects with humanin, the role of SHLP-
1 is still unknown. Humanin and SHLP-2 are reported to be involved in age-related diseases, 
such as Alzheimer’s disease. RA is also an age-related disease, and the SHLP family may be 
involved in the same manner. 
Sorcin is expressed in most human tissues at high levels, in bone, heart, B- and T-
lymphocytes, monocytes, kidney, breast, and skin. Sorcin is found ubiquitously, in the 
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nucleus, cytosols, plasma membranes, and the endoplasmic reticulum (ER). Sorcin 
participates in the regulation of calcium homeostasis. In particular, sorcin increases the 
accumulation of calcium (Ca
2+
) in the ER by activating sarco(endo)plasmic reticulum Ca
2+
 
ATPase (SERCA) and by inhibiting ryanodine receptor (RyR) (Colotti et al., 2014). 
Abnormal Ca
2+
 homeostasis in the ER, e.g., Ca
2+
 depletion, causes ER stress and activates a 
series of adaptive reactions known as the unfolded protein response (UPR). However, 
although the problem remains whether autoantibody can access intracellular protein through 
the cytoplasmic membrane, the anti-sorcin autoantibody may induce the UPR and play a role 
in the progression of RA. Recently, it has been reported that some calcium binding 
chaperones in ER are identified as novel autoantigens in RA and SLE (Weber et al., 2010). 
Therefore, autoantibodies against calcium binding ER-resident chaperones may involve with 
RA. 
In this study, I have also isolated a phage, encoding the N-terminal (7
th
-124
th
) of 
IGFBP-4. Insulin-like growth factors (IGFs) are the most abundant growth factors stored in 
bone. They stimulate both bone cell proliferation and differentiation, and therefore play an 
important role in the regulation of bone formation (McCarthy et al., 1989; Rosen et al., 1994). 
In recent years, it has become known that the effects of IGFs in the bone are regulated by 
IGFBPs, which are six members of a single protein family (IGFBP-1–6) (Rajaram et al., 
1997). IGFBPs bind IGFs with an affinity equal to or greater than the binding of IGFs to their 
receptors, thus IGFBPs have been considered inhibitors of IGFs (Jones et al., 1995). In 
general, IGFBPs act in the serum to transport and stabilize IGFs, and as a result prolong the 
half-lives of IGFs (Mohan et al., 2002). About 75% of the IGFs circulate in serum as a 150 
kDa complex, which consists of IGF-I/IGF-II, IGFBP-3, and an acid-labile subunit (ALS) 
(Mohan et al., 1996). A part of IGFBP-5 also makes this ternary complex, while other 
IGFBPs are found in a smaller 50 kDa binary complex with IGFs. The larger 150 kDa ternary 
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complex cannot cross the endothelial barrier, but the smaller 50 kDa binary complexes are 
able to pass through blood vessels (Rajaram et al., 1997). IGFBP-4 has also been shown to 
inhibit IGF actions in vitro, as do other IGFBPs (Jones et al., 1995; Mohan et al., 1995). 
However, systemic administration of IGFBP-4 at pharmacological doses caused a significant 
increase in bone formation in vivo (Miyakoshi, 2001). They speculated that IGFs may be 
shifted away from IGFBP-3 toward IGFBP-4 due to the systemic administration of IGFBP-4, 
followed by an increase of smaller 50 kDa binary complex. The binary complex of IGF-
I/IGFBP-4 may exit the blood circulation and deliver IGF-I into the bone. Finally, IGFBP-4 
is proteolytically cleaved, releasing free IGFs, which stimulate bone cell proliferation and 
differentiation (Fig. 7). It is indicated that autoantibody against IGFBP-4 exists in the serum 
of RA patients. I speculate that anti-IGFBP-4 autoantibody prevents the transfer of IGF-I 
from IGFBP-3 to IGFBP-4. As a result, IGF-I will not be delivered into the bone, bone 
formation will be inhibited, and finally articular destruction will occur. In fact, the 
autoantibody found in this study recognizes N-terminal (7
th
-124
th
) of IGFBP-4, which is 
consistent with the binding region of IGF-I; therefore the antibody competitively prevents 
IGF-I binding to IGFBP-4. Thus, the autoantibody against IGFBP-4 may participate in the 
progression of RA. 
In this study, to begin I could prove that cytoplasmic proteins can be selected as 
autoantigens of autoimmune diseases from a cDNA phage display library made using the 
λfoo phage vector; besides, some novel autoantigen/autoantibody sets could be found. 
Furthermore, I speculate that some novel autoantigens may involve with clinical 
manifestation. I expect that like these findings are useful to pursue the cause of production 
mechanism of autoantibody and relationship with clinical manifestation, lead the clue to the 
solution of autoimmune diseases. 
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Besides, cDNA libraries constructed with foo may also be searched efficiently for 
proteins physically interacting with macromolecules including proteins, DNA, RNA, and 
polysaccharides immobilized on the surface of solid matrices such as microtiter wells or 
agarose beads. Therefore, they are expected to exert power in searching for not only 
antigen/antibody sets, but also in elucidating the interaction between biological molecules 
such as ligands and receptors or a protein complex. Furthermore, I suggest that describing 
and efficiently discovering new antigens or ligand/receptor couples like in this study, may 
increase opportunities for elucidating the protein-protein interaction in the cell and its 
etiology. 
However, bacteriophage expression vectors including foo may not be efficient for 
epitopes that are post-translationally modified by such a mechanism as citrullination, 
glycosylation or phosphorylation. It is my aim to develop a phage display method in 
eukaryotes in the future. 
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Fig. 7 IGFBP-4 takes up IGF from IGFBP-3 in blood and moves into bone tissue. This 
figure was cited from R&D Systems website 
(https://www.rndsystems.com/resources/articles/igfbp-4-and-bone) 
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